Sciclone Pharmaceuticals, Inc. (SCLN) Misses Q4 EPS by 8c, Guides FY13
Tweet
Share
E-mailGet Alerts SCLN Hot Sheet
Join SI Premium – FREE
Sciclone Pharmaceuticals, Inc. (NASDAQ: SCLN) reported Q4 EPS of $0.04, $0.08 worse than the analyst estimate of $0.12. Revenue for the quarter came in at $33.1 million versus the consensus estimate of $35.3 million.
Sciclone Pharmaceuticals, Inc. sees FY2013 EPS of $0.66-0.72, versus the consensus of $0.65. Sees FY revs of $150 to $155 million vs $153.07 expected.
For earnings history and earnings-related data on Sciclone Pharmaceuticals, Inc. (SCLN) click here.
Sciclone Pharmaceuticals, Inc. sees FY2013 EPS of $0.66-0.72, versus the consensus of $0.65. Sees FY revs of $150 to $155 million vs $153.07 expected.
For earnings history and earnings-related data on Sciclone Pharmaceuticals, Inc. (SCLN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Yalla Group Limited (YALA) Reports Q2 EPS of $0.24
- Is Treasury selloff a major issue for stock market bulls?
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
